IP Library Granted Patent US 10,092,643
Granted Patent B2
US 10,092,643 · App. 11/994,050 · Granted Oct 9, 2018

Prophylactic and immunomodulatory compositions and uses

Inventor: Marc Creus (Geneva, CH)
A61K39/39A61K2039/55544A61K2039/55555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,643
App. No.
11/994,050
Granted
Oct 9, 2018
Kind
B2
Abstract

Provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of a vaccine effective in the treatment and prevention of an infectious disease and treatment and/or prevention of an autoimmune disease. Also provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of an immunomodulation medicament effective in the prevention of infectious disease and treatment and/or prevention of an autoimmune disease.

Claims (10)

1. A method to treat a subject suffering from an autoimmune disease, the method comprising injecting into the subject a composition comprising sphingosine-1-phosphate (SIP) or a salt thereof, as the sole active ingredient and at a concentration from 1 to 200 microM, wherein the autoimmune disease is Crohn's disease, sarcoidosis, or inflammatory bowel disease (IBD), and wherein the concentration of the S1P is effective to reduce chronic inflammation while promoting an immune response, thereby treating the autoimmune disease.

2. The method of claim 1 , wherein the autoimmune disease is Crohn's disease.

3. The method of claim 1 , wherein the composition is injected simultaneously or sequentially with one or more excipients.

4. The method of claim 1 , wherein the composition is a solution, emulsion, or suspension, or is microencapsulated.

5. The method of claim 1 , wherein the autoimmune disease is associated with an infection caused by Mycobacterium tuberculosis.

6. The method of claim 1 , wherein the injection is parenteral.

7. The method of claim 1 , wherein the injection is into the bloodstream.

8. The method of claim 1 , wherein the injection is intravenous.

9. The method of claim 1 , wherein the autoimmune disease is sarcoidosis.

10. The method of claim 1 , wherein the autoimmune disease is inflammatory bowel disease (IBD).

Assignments (3)
CHANGE OF NAME Recorded Aug 1, 2013
From: KHERION BIOTECH INC.
To: KHERION TECHNOLOGY LIMITED
Reel/Frame 030922/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2013
From: KHERION BIOTECH INC.
To: KHERION TECHNOLOGY LIMITED
Reel/Frame 030851/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2009
From: CREUS, MARC
To: KHERION BIOTECH INC.
Reel/Frame 023272/0917 →
Priority Claims (1)
GB 0513431.7 · Jun 30, 2005 · national
Continuity (1)
Related Publication 20100278903A1 · Nov 4, 2010